SCHEMBL5023940

SCHEMBL5023940

Cc1oc(-c2ccc(Br)cc2)nc1CCl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TARBP2 Q15633 1/20 0.50
PPARG P37231 1/20 0.47
PPARA Q07869 1/20 0.47
KDM4E B2RXH2 4/20 0.45
HSD17B10 Q99714 2/20 0.41
RAB9A P51151 6/20 0.41
NPC1 O15118 5/20 0.41
HPGD P15428 2/20 0.41
TSHR P16473 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 2/20 0.41
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
HRH3 Q9Y5N1 1/20 0.40
TP53 P04637 2/20 0.40
PDE4B Q07343 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
DGAT1 O75907 1/20 0.39
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2330165 0.86 TP53 (0.49) TARBP2KDM4EHSD17B10RAB9ANPC1
SCHEMBL924162 0.85 HSD17B10 (0.54) TARBP2PPARAKDM4EHSD17B10HPGD
SCHEMBL4830096 0.83 TARBP2 (0.50) TARBP2PPARGPPARAKDM4EHSD17B10
SCHEMBL1931219 0.83 ALDH1A1 (0.51) PPARGPPARAKDM4EHSD17B10RAB9A
SCHEMBL14431360 0.83 TARBP2 (0.50) TARBP2PPARGPPARAKDM4EHSD17B10
SCHEMBL5093853 0.83 TARBP2 (0.54) TARBP2PPARGPPARAKDM4EHSD17B10
SCHEMBL3996100 0.83 TARBP2 (0.50) TARBP2PPARGPPARAKDM4EHSD17B10
SCHEMBL503999 0.83 KDM4E (0.64) TARBP2PPARGPPARAKDM4ERAB9A
SCHEMBL25307839 0.82 KDM4E (0.44) PPARGKDM4EHSD17B10RAB9ANPC1
SCHEMBL4359109 0.82 KDM4E (0.56) TARBP2PPARGPPARAKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7446127-B2 Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders SK HOLDINGS CO, LTD. (KR) 2008-11-04 US disclosed
US-20080146631-A1 OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS BROOKS DAWN ALISA 2008-06-19 US disclosed
US-20080146631-A1 OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS BROOKS DAWN ALISA 2008-06-19 US disclosed
US-20080146631-A1 OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS BROOKS DAWN ALISA 2008-06-19 US disclosed
US-7351728-B2 Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists ELI LILLY AND COMPANY (US) 2008-04-01 US disclosed
US-7351728-B2 Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists ELI LILLY AND COMPANY (US) 2008-04-01 US disclosed
US-7351728-B2 Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists ELI LILLY AND COMPANY (US) 2008-04-01 US disclosed
EP-1313715-B1 OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS LILLY CO ELI (US) 2007-08-01 EP disclosed
EP-1313715-B1 OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS LILLY CO ELI (US) 2007-08-01 EP disclosed
EP-1660490-A1 CHROMAN CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS SK Corporation (KR) 2006-05-31 EP disclosed
US-6982278-B2 Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists ELI LILLY AND COMPANY (US) 2006-01-03 US disclosed
US-20050250825-A1 Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists BROOKS DAWN A 2005-11-10 US disclosed
US-20050107371-A1 Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders SK BIOPHARMACEUTICALS CO., LTD. (KR) 2005-05-19 US disclosed
US-20050075378-A1 Modulators of peroxisome proliferator activated receptors (ppar) ELI LILLY AND COMPANY 2005-04-07 US disclosed
WO-2005021540-A1 CHROMAN CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS SK CORPORATION (KR) 2005-03-10 WO disclosed
US-20040024034-A1 Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists BROOKS DAWN ALISA (US) 2004-02-05 US disclosed
US-20040019090-A1 2-(4-(2-(2-biphenyl-yl-5-methyl-thiazol-4-yl)-alkoxy)-phenoxy) -2-methyl-propionic acid derivatives; antidiabetic agents ELI LILLY & COMPANY 2004-01-29 US disclosed
EP-1313715-A1 OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS ELI LILLY AND COMPANY (US) 2003-05-28 EP disclosed
WO-2002018355-A1 OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS ELI LILLY AND COMPANY (US) 2002-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250825-A1 Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists PPARA, PPARG, PPARD TARBP2 4491/4885PPARG 2/4885PPARA 1/4885
US-20040024034-A1 Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists PPARA, PPARG, PPARD TARBP2 4537/4885PPARG 2/4885PPARA 1/4885
US-20050075378-A1 Modulators of peroxisome proliferator activated receptors (ppar) PPARG, PPARA, PPARD TARBP2 2716/4885PPARG 1/4885PPARA 2/4885
US-20040019090-A1 2-(4-(2-(2-biphenyl-yl-5-methyl-thiazol-4-yl)-alkoxy)-phenoxy) -2-methyl-propionic acid derivatives; antidiabetic agents SLC5A2, SLC5A1, GLP1R TARBP2 2996/4885PPARG 26/4885PPARA 19/4885
US-20080146631-A1 OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS PPARA, PPARG, PPARD TARBP2 4382/4885PPARG 2/4885PPARA 1/4885
US-20050107371-A1 Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders GPR119, CEL, ACACA TARBP2 3860/4885PPARG 44/4885PPARA 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.